News blog

First drug company to dive into the HIV patent pool may help others take the plunge

Just shy of its one-year anniversary on 16 July, a major international patent sharing organzition has signed up its first industry partner. The Californian drugmaker Gilead Sciences agreed this week to license four of its HIV drug patents — tenofovir, emtricitabine, cobicistat and elvitegravir — along with a combination of the four, dubbed the Quad.

BACK TO ARTICLE

Tell a Friend

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.

BACK TO ARTICLE